hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 14:10:29 - browse：6

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： AI used to predict Covid

WSS

Health Care Service Corp to buy Cigna Medicare Advantage plans

Humana’s losses in Medicare Advantage tank its stock

AI used to predict Covid

Bernie Sanders is gearing up to subpoena pharma CEOs

Venture capital firm's plans to take over Akron hospital face hurdles

Health insurers say they are turning to AI to cut costs, improve care

leisure time

hotspot

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Investment in vaccine development is lagging, report finds

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Adam's Biotech Scorecard: Do Sarepta's exon

Medical leaders decry Supreme Court decision on affirmative action

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Anesthesiologist group: stop taking Ozempic before surgery

Scientists successfully use ultrasound imaging to map brain activity

Dobbs anniversary: the lost opportunity of abortion as health care

Why Medicare shouldn’t cover every FDA

Wikipedia

Insmed lung disease drug hits target in key Phase 3 trial

Merck, Johnson & Johnson CEOs will testify on high drug prices

First Opinion Podcast: What happens when kids become caregivers?

Why Medicare shouldn’t cover every FDA

Health insurers say they are turning to AI to cut costs, improve care

iTeos Therapeutics debuts first data on TIGIT

leisure time

knowledge

focus

leisure time